Company: SVREW
Filing Date: 2025-03-21
Form Type: 20-F
Source: 0001013762-25-001028
Chunk: 45

Company: SaverOne 2014 Ltd.
Filing Date: 2025-03-21
Form: 20-F
Item: Item 3
Chunk 45
---
ilitary reserve duty call-ups in the future. Our operations could be disrupted by the absence of a significant number of our officers,
directors, employees and consultants. Such disruption could materially adversely affect our business and operations.

Your
rights and responsibilities as a shareholder will be governed by Israeli law, which differs in some material respects from the rights
and responsibilities of shareholders of U. S. companies.

The
rights and responsibilities of the holders of our ordinary shares (and therefore indirectly, our ADSs) are governed by our Articles of
Association and by Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities
of shareholders in typical U. S.-based corporations. In particular, a shareholder of an Israeli company has certain duties to act in good
faith and fairness toward the company and other shareholders and to refrain from abusing its power in the company, including, among other
things, in voting at the general meeting of shareholders on certain matters, such as an amendment to the company’s articles of
association, an increase of the company’s authorized share capital, a merger of the company, and approval of related party transactions
that require shareholder approval. In addition, a shareholder who is aware that it possesses the power to determine the outcome of a
shareholder vote or to appoint or prevent the appointment of a director or executive officer in the company has a duty of fairness toward
the company with regard to such vote or appointment. There is limited case law available to assist us in understanding the nature of
this duty or the implications of these provisions. These provisions may be interpreted to impose additional obligations on holders of
our ordinary shares that are not typically imposed on shareholders of U. S. corporations.

Certain
of our research and development activities and programs were supported by Israeli Governmental grants, some of which were sold or
are in the process of selling. The terms of such grants may require us to pay royalties and to satisfy specified conditions in order
to manufacture products and transfer technologies outside of Israel. We may be required to pay penalties in addition to repayment of
the grants.

Our
research and development efforts relating to our products have been financed in part through royalty-bearing grants in an aggregate amount
of approximately NIS 1.7 million (approximately $0.5 million) received from the Israel Innovation Authority, or the IIA, as of December
31, 2024. With respect to the royalty-bearing grants we are committed to pay royalties at a rate of 3% on sales proceeds from our products